Mn Services Vermogensbeheer Increases Bristol Myers Squibb Stake

The Dutch asset manager raised its position in the pharmaceutical company by 2.9% in Q4 2025.

Mar. 31, 2026 at 9:53am

Got story updates? Submit your updates here. ›

An extreme close-up of highly detailed, metallic pharmaceutical manufacturing equipment, conveying the complex, industrial nature of modern drug development without using any text or identifiable branding.Mn Services Vermogensbeheer's increased stake in Bristol Myers Squibb signals ongoing institutional confidence in the pharmaceutical company's advanced manufacturing capabilities and innovative pipeline.Princeton Today

Mn Services Vermogensbeheer B.V., a Netherlands-based asset management firm, increased its stake in Bristol Myers Squibb Company (NYSE: BMY) by 2.9% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 791,736 shares of the biopharmaceutical company's stock, valued at $42.7 million.

Why it matters

This move by Mn Services Vermogensbeheer, a major institutional investor, signals continued confidence in Bristol Myers Squibb's growth prospects and the firm's ability to generate returns for shareholders. Bristol Myers Squibb is a leading global biopharmaceutical company focused on developing innovative cancer and immune-mediated disease treatments.

The details

Mn Services Vermogensbeheer acquired an additional 22,182 shares of Bristol Myers Squibb during the fourth quarter, increasing its total position by 2.9%. The asset manager now holds over $42 million worth of BMY stock. Several other institutional investors and hedge funds also bought and sold shares of Bristol Myers Squibb during the quarter, reflecting ongoing interest in the company's pipeline and commercial performance.

  • Mn Services Vermogensbeheer filed its Q4 2025 13F report with the SEC on March 31, 2026.
  • The firm increased its Bristol Myers Squibb stake during the fourth quarter of 2025.

The players

Mn Services Vermogensbeheer B.V.

A Netherlands-based asset management firm that raised its position in Bristol Myers Squibb Company during Q4 2025.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing innovative cancer and immune-mediated disease treatments.

Got photos? Submit your photos here. ›

The takeaway

Mn Services Vermogensbeheer's increased investment in Bristol Myers Squibb reflects ongoing institutional confidence in the pharmaceutical company's growth potential and ability to deliver shareholder value through its diverse pipeline of new therapies.